共 24 条
- [2] Clinical significance of the monoclonal gammopathy of undetermined significance (MGUS)-like phenotype in patients with AL amyloidosis treated with Bortezomib-Containing Regimens (BCR) at the Amyloidosis Program of Calgary (APC) AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 : S127 - S128
- [4] Comparison of three bortezomib-containing regimens for the treatment of newly diagnosed AL amyloidosis AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 : S122 - S123
- [5] Clinical outcomes for patients with stage III AL amyloidosis: experience from the amyloidosis program of Calgary AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 : S124 - S125
- [6] Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2020, 27 (04): : 244 - 249
- [10] Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (06): : E79 - E84